La vendita allo scoperto per Vapotherm Inc dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Vapotherm Inc. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Vapotherm Inc (OTC:VAPO) Azioni, Report sulle vendite allo scoperto

Vapotherm

Vapotherm Inc

Vapor Group Inc

VAPORBRANDS INTL INC by VaporBrands International, Inc.

VaporBrands International Inc

<ul>
<li>75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy &nbsp;</li>
<li>Data will be presented on Monday, December 9, 2024 at 4:00 PM PT</li>
</ul>
LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 7-10, 2024.

Biotech

News

General

IMMX

Immix Biopharma Presents NXC-201 Clinical Data In 16 Relapsed/Refractory AL Amyloidosis Patients At 66th American Society of Hematology (ASH) Annual Meeting; 75% (12/16) Complete Response Rate Observed In Relapsed/Refractory AL Amyloidosis Patients With Median 4 Prior Lines Of Therapy

U.S. Supreme Court Declines To Decide Whether Certain Federally Mandated Health Warnings On Cigarette Packs Violate Tobacco Companies' Free Speech Protections

Piper Sandler analyst Mark Lear maintains LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) with a Neutral and raises the price target from $39 to $79.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on LandBridge, Raises Price Target to $79

Barclays analyst Ramsey El-Assal maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $64 to $75.

AFRM

Barclays Maintains Overweight on Affirm Holdings, Raises Price Target to $75

Piper Sandler analyst Quinton Gabrielli initiates coverage on SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Neutral rating and announces Price Target of $198.

Initiation

SPSC

Piper Sandler Initiates Coverage On SPS Commerce with Neutral Rating, Announces Price Target of $198

Western Digital's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NYSE">WDC</a>) short percent of float has fallen 9.85% since its last report. The company recently reported that it has 16.25 million shares sold short, which is 5.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.55 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Western Digital Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Western Digital has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Western Digital's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Western Digital's peer group average for short interest as a percentage of float is 6.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Western Digital's Recent Short Interest

Mike Tyson's cannabis brand TYSON 2.0 will debut in Jamaica, the brand's holding company, Carma HoldCo Inc, confirmed Friday. In partnership with NUGL Inc's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NUGL#OTC">NUGL</a>) Kaya Group, TYSON 2.0 will bring its popular line of infused pre-rolls, vapes, pre-packaged flower and concentrates to Jamaican consumers.
Kaya is one of Jamaica's leading medical marijuana companies. Kaya&#8217;s diverse operations include a licensed cultivation facility, processing facility, 3 retail herb houses and one ganja franchise in Punta Del Este, Uruguay. Kaya was the first medicinal Ganja Herb House in the Caribbean. This partnership marks TYSON 2.0&#8217;s entrance into the Caribbean.
Initially, TYSON products will be available at Kaya Herb House locations in St. Ann, Falmouth and in Kingston, with plans to expand into additional retail outlets across Jamaica.
"Bringing TYSON 2.0 to Jamaica is about more than expansion; it&#8217;s about honoring the island's deep-rooted relationship with cannabis," stated Mike Tyson, co-founder and chief brand officer of TYSON 2.0. "Jamaican consumers can now experience the same high quality and dedication we put into every TYSON 2.0 product. I'm excited to share this journey with them."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41685387/mike-tysons-marijuana-brand-tyson-2-0-expands-to-arizona-via-partnership-with-desert-fairways">Mike Tyson&#8217;s Marijuana Brand TYSON 2.0 Expands To Arizona Via Partnership With Desert Fairways</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Adam Wilks, CEO of Carma HoldCo, added, "Expanding into Jamaica is another big win for TYSON 2.0 and Carma HoldCo. Like Amsterdam, Jamaica is a global leader in cannabis culture, making it the perfect destination for our next chapter. Partnering with Kaya Group allows us to merge our premium product lineup with a rich heritage, providing discerning consumers with an unmatched cannabis experience."
Bali Vaswani, CEO of Kaya Group and NUGL, remarked on the partnership's significance: "Our collaboration with TYSON is another defining moment for Jamaica&#8217;s ganja industry. By combining our local expertise in cultivation, processing and our commitment to quality with TYSON 2.0's global reach, we're creating one-of-a-kind ganja experiences. Every herb has a story, and together we're bringing those stories to life, connecting our community to the world."
Since its debut in 2021, TYSON 2.0 expanded beyond the U.S. and into 16 countries and broadened its portfolio to include other premium product categories, cementing its reputation for crafting memorable experiences.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39612472/mike-tyson-to-open-first-branded-retail-store-in-amsterdam-a-city-that-always-held-a-special-pla">Mike Tyson To Open First Branded Retail Store In Amsterdam, A City That Always Held A Special Place In His Heart</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41693389/exclusive-mike-tyson-and-st-ndenglass-unveil-the-tyson-2-0-mod-l-dok-travel-set">EXCLUSIVE: Mike Tyson And Stündenglass Unveil The TYSON 2.0 Modül + Dok Travel Set</a></li>
</ul>
Courtesy Photo

Cannabis

NUGL

Mike Tyson's Cannabis Infused Pre-Rolls And Vapes Reach Jamaica Via Kaya Group Partnership

Modine Manufacturing's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) short percent of float has fallen 7.21% since its last report. The company recently reported that it has 3.43 million shares sold short, which is 7.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Modine Manufacturing Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545016_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Modine Manufacturing has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Modine Manufacturing's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Modine Manufacturing's peer group average for short interest as a percentage of float is 6.81%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Modine Manufacturing's Recent Short Interest

First Solar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>) short percent of float has risen 20.26% since its last report. The company recently reported that it has 6.01 million shares sold short, which is 7.36% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>First Solar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732545011_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for First Solar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing First Solar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, First Solar's peer group average for short interest as a percentage of float is 4.60%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

FSLR

(FSLR) - Analyzing First Solar's Short Interest

Piper Sandler analyst Quinton Gabrielli initiates coverage on Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Overweight rating and announces Price Target of $326.

MANH

Piper Sandler Initiates Coverage On Manhattan Associates with Overweight Rating, Announces Price Target of $326

Benchmark analyst Mark Palmer maintains MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $450 to $650.

MSTR

Benchmark Maintains Buy on MicroStrategy, Raises Price Target to $650

Barclays analyst Saket Kalia maintains Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) with a Equal-Weight and raises the price target from $34 to $44.

NCNO

Barclays Maintains Equal-Weight on Ncino, Raises Price Target to $44

On Monday, Cassava Sciences Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock plunged after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42160859/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints" rel="noreferrer noopener">Alzheimer&#8217;s disease</a>.
The trial did not meet the pre-specified co-primary, secondary, and exploratory biomarker endpoints.
In July, CEO Rick Barry wrote a letter to shareholders and employees, saying that the company is in the final stages of testing simufilam and has significant&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41065699/sec-charges-cassava-sciences-over-manipulated-alzheimers-trial-data-company-and-former-execs-agre" rel="noreferrer noopener">financial and emotional stakes</a>.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo.
Simufilam continued to demonstrate an overall favorable safety profile.
&#8220;The results are disappointing&#8230;We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD&#8230;&#8221; said&nbsp;Rick Barry, President and Chief Executive Officer.
The company said the failed trial results have impacted its second Phase 3 trial,&nbsp;ReFocus-ALZ, and decided to discontinue ReFocus-ALZ. The company will also be discontinuing the Open Label Extension study.
The complete 52-week dataset will be available from the study along with a large portion of 76-week data.
Cassava will continue to review the data and evaluate the next steps. We plan to share the detailed results at a future medical meeting.
Cassava has been in the headlines for fabricating data from <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41231890/whats-going-on-with-alzheimers-focused-cassava-sciences-on-tuesday" rel="noreferrer noopener">simufilam drug trials</a>.
In September, Cassava Sciences&nbsp;agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company&#8217;s controversial&nbsp;Alzheimer&#8217;s drug, simufilam.
The SEC also&nbsp;charged&nbsp;Hoau-Yan Wang, a consultant and co-developer of the drug, with manipulating trial results.
The SEC&#8217;s investigation found that in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/21/08/22653801/cassava-sciences-shares-sink-with-alzheimers-drug-mired-in-controversy" rel="noreferrer noopener">September 2020</a>, Cassava disclosed manipulated data from the trial, which falsely suggested dramatic improvements in Alzheimer&#8217;s biomarkers like total tau and phosphorylated tau.
Price Action: SAVA stock is down 84.2% at $4.19 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market" target="_blank" rel="noreferrer noopener">FDA Approves BridgeBio Pharma&#8217;s Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market</a></li>
</ul>

Equities

Health Care

Movers

SAVA

Cassava Sciences' Controversial Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Halts Late-Stage Studies

Barclays analyst Alexia Dogani maintains ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) with a Underweight and raises the price target from $13.9 to $16.5.

Barclays Maintains Underweight on ZIM Integrated Shipping, Raises Price Target to $16.5

Semler Scientific Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher Monday. The company launched an offering and provided an update on its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/pressreleases/24/11/n42160050/semler-scientific-announces-updated-btc-and-atm-activity">holdings</a>.
What Happened: Semler Scientific announced that it acquired 297 Bitcoin for $29.1 million in cash between Nov. 18 and Nov. 22. The company made the purchases at an average price of $97,995 per Bitcoin. 
As of Friday, Semler held a total of 1,570 Bitcoin, acquired for an aggregate of $117.8 million. 
Semler Scientific entered into a Controlled Equity Offering&nbsp;Sales Agreement with Cantor Fitzgerald in August, under which Semler may offer and sell its common stock in an at-the-market offering from time to time.
The company filed a prospectus supplement on Monday to offer an additional $50 million of shares under its existing offering with Cantor, bringing the total offering amount up to $100 million. 
Several crypto-related stocks have rallied in recent weeks as Bitcoin prices have climbed to new all-time highs just below the $100,000 level. Bitcoin was up 0.24% over a 24-hour period, trading at $97,700 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42155055/crypto-analyst-bitcoin-poised-to-skyrocket-to-180k-and-eventually-top-1m#google_vignette">Crypto Analyst: Bitcoin Poised To Skyrocket To $180K and &#8216;Eventually&#8217; Top $1M</a>
SMLR Price Action: Semler Scientific shares were up 5.11% at $66.90 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Offerings

$BTC

SMLR

What's Going On With Semler Scientific Stock Monday?

JP Morgan analyst Michael Rehaut maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Overweight and raises the price target from $48 to $58.

AZEK

JP Morgan Maintains Overweight on AZEK Co, Raises Price Target to $58

Morgan Stanley analyst Erik Woodring reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and maintains $273 price target.

Reiteration

AAPL

Morgan Stanley Reiterates Overweight on Apple, Maintains $273 Price Target

JP Morgan analyst Eric Joseph maintains TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Overweight and raises the price target from $30 to $43.

TGTX

JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $43

Morgan Stanley analyst Devin McDermott maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $45 to $56.

Morgan Stanley Maintains Overweight on EQT, Raises Price Target to $56

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) has completed the second and final closing of its previously announced non-brokered private placement of its common shares at $0.06 per common share.
<h3 class="wp-block-heading">What Happened</h3>
The company said on Monday that, at the second closing of the offering, it issued 19,647,776 common shares for gross proceeds of roughly $1,178,867.
The second closing was in addition to the previously announced first closing in November when Decibel issued 33,503,864 common shares for gross proceeds of approximately $2,010,232.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel's $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Why It Matters</h3>
Decibel said the proceeds of the offering will be used to work on and help integrate the integration of AgMedica BioScience Inc. which he company previously<a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance"> acquired</a>. The acquisition was arranged through an agreement with Callisto Capital on Oct. 28 and was made in exchange for a $6.3 million unsecured convertible debenture.
Decibel projects that AgMedica could contribute $30 million of net revenue and $4 million of EBITDA in 2025, totaling an anticipated $130 million of net revenue and $25 million of adjusted EBITDA in 2025 on a pro forma basis.
The company recently <a href="https://www.benzinga.com/24/11/42137701/canadian-cannabis-co-decibel-reports-12-yoy-drop-in-q3-revenue-but-increases-gross-margin-to-53">announced</a> its unaudited interim financial results on Thursday for the third quarter revealing CA$24.1 million ($17.2 million) in net revenue representing a 9% increase sequentially, but a 12% decrease year-over-year. However, gross margin before fair value adjustments reached 53% for the period, up from 44% in the prior year&#8217;s period, reflecting improved operational efficiency.
<h3 class="wp-block-heading">What's Next</h3>
The offering is subject to the receipt of all regulatory approvals including the final approval of the TSX Venture Exchange (TSXV).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 1.45% higher at $0.0476 per share after the market close on Friday afternoon.

Financing

DBCCF

TSXV:DB

Decibel Cannabis Raises $1.18M, Secures Capital For AgMedica BioScience Integration

Vapotherm Inc (VAPO) stock has fallen -91.92% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives VAPO stock a score of  0 out of a possible 100. That rank is mainly influenced by a short-term technical score of 0. VAPO's rank also includes a long-term technical score of 0.  VAPO has an Overall S

Is Vapotherm Inc (VAPO) Stock Worth a Buy Friday?

Vapotherm Inc (VAPO) just unveiled an update. Vapotherm, Inc. has implemented a strategic move to reprice stock options, reducing the exercise pric...

Vapotherm Inc Reprices Stock Options to Retain Key Personnel

Vapotherm Inc (VAPO) has provided an announcement. Vapotherm, Inc. has secured a new $4.0 million senior secured term loan B facility with SLR Inve...

Vapotherm Secures New $4 Million Senior Secured Loan

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vapotherm (NYSE:<a href="https://investorplace.com/stock-quotes/vapo-stock-quote/">VAPO</a>) just reported results for the first quarter of 2024.<ul><li>Vapotherm reported earnings per share of -$2.31.</li><li>The company reported revenue of $19.13 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/vapo-stock-earnings-vapotherm-for-q1-of-2024/">VAPO Stock Earnings: Vapotherm Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VAPO Stock Earnings: Vapotherm Reported Results for Q1 2024

Vapotherm GAAP EPS of -$2.31, revenue of $19.1M

Vapotherm to go private by way of a merger

Vapotherm (VAPO) just unveiled an announcement. Vapotherm, Inc. has entered into a merger agreement with Veronica Holdings, LLC and its affiliated ...

Vapotherm's Strategic Merger and Executive Leadership Changes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vapotherm (NYSE:<a href="https://investorplace.com/stock-quotes/vapo-stock-quote/">VAPO</a>) just reported results for the second quarter of 2024.<ul><li>Vapotherm reported earnings per share of -$2.22.</li><li>The company reported revenue of $16.88 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vapo-stock-earnings-vapotherm-for-q2-of-2024/">VAPO Stock Earnings: Vapotherm Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VAPO Stock Earnings: Vapotherm Reported Results for Q2 2024

Vapotherm GAAP EPS of -$2.22, revenue of $16.9M

The latest announcement is out from Vapotherm ( ($VAPO) ). Vapotherm, Inc. has successfully completed a merger with an entity backed by Perceptive ...

Vapotherm's Strategic Merger, Equity Shifts, and OTCQX Delisting

VAPO

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, PRMW, SILK, VAPO on Behalf of Shareholders

Small Cap

Kuehn Law Encourages INFN, RPHM, VAPO, and PRFT Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, VAPO, PRFT on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, SRDX, AGS, VAPO on Behalf of Shareholders

Penny Stocks

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Vapotherm, Inc. - VAPO

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPR, DO, VAPO on Behalf of Shareholders

Earnings

Vapotherm Reports Second Quarter 2024 Financial Results

VAPOTHERM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vapotherm, Inc. - VAPO

Comments

Vapotherm Inc

Vendite allo scoperto

Vapotherm Inc (OTC:VAPO) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO